These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

384 related items for PubMed ID: 16009387

  • 1. Effects of novel antipsychotics with mixed D(2) antagonist/5-HT(1A) agonist properties on PCP-induced social interaction deficits in the rat.
    Bruins Slot LA, Kleven MS, Newman-Tancredi A.
    Neuropharmacology; 2005 Dec; 49(7):996-1006. PubMed ID: 16009387
    [Abstract] [Full Text] [Related]

  • 2. Partial agonist properties of the antipsychotics SSR181507, aripiprazole and bifeprunox at dopamine D2 receptors: G protein activation and prolactin release.
    Cosi C, Carilla-Durand E, Assié MB, Ormiere AM, Maraval M, Leduc N, Newman-Tancredi A.
    Eur J Pharmacol; 2006 Mar 27; 535(1-3):135-44. PubMed ID: 16554049
    [Abstract] [Full Text] [Related]

  • 3. SSR181507, a putative atypical antipsychotic with dopamine D2 antagonist and 5-HT1A agonist activities: improvement of social interaction deficits induced by phencyclidine in rats.
    Boulay D, Depoortère R, Louis C, Perrault G, Griebel G, Soubrié P.
    Neuropharmacology; 2004 Jun 27; 46(8):1121-9. PubMed ID: 15111019
    [Abstract] [Full Text] [Related]

  • 4. Contrasting contribution of 5-hydroxytryptamine 1A receptor activation to neurochemical profile of novel antipsychotics: frontocortical dopamine and hippocampal serotonin release in rat brain.
    Assié MB, Ravailhe V, Faucillon V, Newman-Tancredi A.
    J Pharmacol Exp Ther; 2005 Oct 27; 315(1):265-72. PubMed ID: 15987834
    [Abstract] [Full Text] [Related]

  • 5. Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade.
    Auclair AL, Kleven MS, Besnard J, Depoortère R, Newman-Tancredi A.
    Neuropsychopharmacology; 2006 Sep 27; 31(9):1900-9. PubMed ID: 16421514
    [Abstract] [Full Text] [Related]

  • 6. Clozapine, ziprasidone and aripiprazole but not haloperidol protect against kainic acid-induced lesion of the striatum in mice, in vivo: role of 5-HT1A receptor activation.
    Cosi C, Waget A, Rollet K, Tesori V, Newman-Tancredi A.
    Brain Res; 2005 May 10; 1043(1-2):32-41. PubMed ID: 15862515
    [Abstract] [Full Text] [Related]

  • 7. Antipsychotics differ in their ability to internalise human dopamine D2S and human serotonin 5-HT1A receptors in HEK293 cells.
    Heusler P, Newman-Tancredi A, Loock T, Cussac D.
    Eur J Pharmacol; 2008 Feb 26; 581(1-2):37-46. PubMed ID: 18190908
    [Abstract] [Full Text] [Related]

  • 8. F15063, a potential antipsychotic with dopamine D(2)/D(3) receptor antagonist and 5-HT(1A) receptor agonist properties: influence on immediate-early gene expression in rat prefrontal cortex and striatum.
    Bruins Slot LA, Lestienne F, Grevoz-Barret C, Newman-Tancredi A, Cussac D.
    Eur J Pharmacol; 2009 Oct 12; 620(1-3):27-35. PubMed ID: 19695244
    [Abstract] [Full Text] [Related]

  • 9. Novel antipsychotic agents with 5-HT(1A) agonist properties: role of 5-HT(1A) receptor activation in attenuation of catalepsy induction in rats.
    Kleven MS, Barret-Grévoz C, Bruins Slot L, Newman-Tancredi A.
    Neuropharmacology; 2005 Aug 12; 49(2):135-43. PubMed ID: 15996562
    [Abstract] [Full Text] [Related]

  • 10. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist, alleviates disturbances of novelty discrimination in a social context in rats, a putative model of selective attention deficit.
    Terranova JP, Chabot C, Barnouin MC, Perrault G, Depoortere R, Griebel G, Scatton B.
    Psychopharmacology (Berl); 2005 Aug 12; 181(1):134-44. PubMed ID: 15830220
    [Abstract] [Full Text] [Related]

  • 11. Phencyclidine-induced cognitive deficits in mice are improved by subsequent subchronic administration of the antipsychotic drug perospirone: role of serotonin 5-HT1A receptors.
    Hagiwara H, Fujita Y, Ishima T, Kunitachi S, Shirayama Y, Iyo M, Hashimoto K.
    Eur Neuropsychopharmacol; 2008 Jun 12; 18(6):448-54. PubMed ID: 18164909
    [Abstract] [Full Text] [Related]

  • 12. Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties.
    Bardin L, Kleven MS, Barret-Grévoz C, Depoortère R, Newman-Tancredi A.
    Neuropsychopharmacology; 2006 Sep 12; 31(9):1869-79. PubMed ID: 16237379
    [Abstract] [Full Text] [Related]

  • 13. Differential profile of antipsychotics at serotonin 5-HT1A and dopamine D2S receptors coupled to extracellular signal-regulated kinase.
    Bruins Slot LA, De Vries L, Newman-Tancredi A, Cussac D.
    Eur J Pharmacol; 2006 Mar 18; 534(1-3):63-70. PubMed ID: 16497294
    [Abstract] [Full Text] [Related]

  • 14. SSR181507, a dopamine D(2) receptor antagonist and 5-HT(1A) receptor agonist. I: Neurochemical and electrophysiological profile.
    Claustre Y, Peretti DD, Brun P, Gueudet C, Allouard N, Alonso R, Lourdelet J, Oblin A, Damoiseau G, Françon D, Suaud-Chagny MF, Steinberg R, Sevrin M, Schoemaker H, George P, Soubrié P, Scatton B.
    Neuropsychopharmacology; 2003 Dec 18; 28(12):2064-76. PubMed ID: 12902994
    [Abstract] [Full Text] [Related]

  • 15. In vitro and in vivo characterization of F-97013-GD, a partial 5-HT1A agonist with antipsychotic- and antiparkinsonian-like properties.
    Zazpe A, Artaiz I, Innerárity A, Del Olmo E, Castro E, Labeaga L, Pazos A, Orjales A.
    Neuropharmacology; 2006 Jul 18; 51(1):129-40. PubMed ID: 16643965
    [Abstract] [Full Text] [Related]

  • 16. SSR181507, a dopamine D2 receptor antagonist and 5-HT1A receptor agonist. II: Behavioral profile predictive of an atypical antipsychotic activity.
    Depoortere R, Boulay D, Perrault G, Bergis O, Decobert M, Françon D, Jung M, Simiand J, Soubrié P, Scatton B.
    Neuropsychopharmacology; 2003 Nov 18; 28(11):1889-902. PubMed ID: 12902993
    [Abstract] [Full Text] [Related]

  • 17. SSR181507, a dopamine D₂ receptor and 5-HT(₁A) receptor ligand: evidence for mixed anxiolytic- and antidepressant-like activities.
    Boulay D, Depoortere R, Louis C, Lacave M, Lucas MT, Griebel G.
    Pharmacol Biochem Behav; 2011 Jan 18; 97(3):428-35. PubMed ID: 20920519
    [Abstract] [Full Text] [Related]

  • 18. Effects of bifeprunox and aripiprazole on rat serotonin and dopamine neuronal activity and anxiolytic behaviour.
    Dahan L, Husum H, Mnie-Filali O, Arnt J, Hertel P, Haddjeri N.
    J Psychopharmacol; 2009 Mar 18; 23(2):177-89. PubMed ID: 18515444
    [Abstract] [Full Text] [Related]

  • 19. Differences among conventional, atypical and novel putative D(2)/5-HT(1A) antipsychotics on catalepsy-associated behaviour in cynomolgus monkeys.
    Auclair AL, Kleven MS, Barret-Grévoz C, Barreto M, Newman-Tancredi A, Depoortère R.
    Behav Brain Res; 2009 Nov 05; 203(2):288-95. PubMed ID: 19464324
    [Abstract] [Full Text] [Related]

  • 20. The effect of serotonin(1A) receptor agonism on antipsychotic drug-induced dopamine release in rat striatum and nucleus accumbens.
    Ichikawa J, Meltzer HY.
    Brain Res; 2000 Mar 10; 858(2):252-63. PubMed ID: 10708676
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.